vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and...
95 insider purchases on record · latest filing 2024-11-19.
Insiders have also filed 1 sale transaction at VTVT.